Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation (Q44070526)

29 November 2017

Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation (English)

1 reference

29 November 2017

0 references

Yoshiko Hirano

1

1 reference

29 November 2017

Fuminori Hirano

series ordinal

2

1 reference

29 November 2017

Hiroshi Fujii

series ordinal

3

1 reference

29 November 2017

Isao Makino

series ordinal

4

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

European Journal of Pharmacology

29 November 2017

1 reference

29 November 2017

448

1 reference

29 November 2017

1

1 reference

29 November 2017

19-26

1 reference

Influence of oral treatment with ursodeoxycholic and tauroursodeoxycholic acids on estrogen-induced cholestasis in rats: effects on bile formation and liver plasma membranes

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Peroxisome proliferator-activated receptors in inflammation control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Peroxisome proliferator-activated receptors: nuclear control of metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Identification of a nuclear receptor that is activated by farnesol metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Functional interference of Sp1 and NF-kappaB through the same DNA binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Alternative splicing variants of IkappaB beta establish differential NF-kappaB signal responsiveness in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Bile acids regulate RANTES gene expression through its cognate NF-kappaB binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Pruritus associated with cholestasis. A review of pathogenesis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Differential expression and activation of a family of murine peroxisome proliferator-activated receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

CD4+ T cell subsets defined by isoforms of CD45 in primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Immunophenotyping of lymphocytes in liver tissue of patients with chronic liver diseases by flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Identification of a nuclear receptor for bile acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Bile acids: natural ligands for an orphan nuclear receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Chemokines and T lymphocytes: more than an attraction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901902-7

10.1016/S0014-2999(02)01902-7

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference